1414 - PD-L1 testing for access to Pembrolizumab for the treatment of locally advanced or metastatic NSCLC
Page last updated: 27 March 2017
Application Detail
Status
Open
Description of Medical Service
TImmunoHistoChemistry (IHC) test for evaluation of Programmed Cell Death 1 Ligand (PD-L1) expression to determine eligibility for treatment with Pembrolizumab.
Description of Medical Condition
Locally advanced or metastatic NSCLC (Stage IIIb/IV).